, ,
,
,
, ‘Celltrion’s stock price is on the rise with news that the company has received approval for a clinical plan for an immune checkpoint inhibitor biosimilar from the U.S. Food and Drug Administration (FDA).’,
,
, ‘As of 9:08 a.m. on the 12th, Celltrion is trading at 203,000 won, up 7,000 won (3.57%) from the previous trading day.’,
,
, “Earlier, Celltrion announced that it received FDA approval for the Investigational New Drug (IND) application for CT-P51, a biosimilar of ‘Keytruda’ (generic name: pembrolizumab).”,
,
, ‘Celltrion plans to demonstrate the equivalence and efficacy between the original drug and CT-P51 in a phase 3 clinical trial involving 606 patients with metastatic non-small cell lung cancer.’,
,
, ‘Keytruda, developed by the global pharmaceutical company Merck, is a blockbuster drug indicated for non-small cell lung cancer, stomach cancer, and head and neck cancer.’,
,
, ‘It achieved record sales of $25 billion (approximately 34 trillion won) last year, making it the top-selling drug worldwide.’,
,